Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients

NCT03760822 is registered in ClinicalTrials.gov with Federation Francophone de Cancerologie Digestive as lead sponsor.

NCT NCT03760822
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03760822 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Lead sponsor
Federation Francophone de Cancerologie Digestive
Phase
Phase 2
Overall status
Unknown status
Start date
November 16, 2018
Completion date
December 31, 2024
Enrollment
112 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer, gastroesophageal junction adenocarcinoma, stomach cancer, stomach neoplasm